Agios Pharm Stock Investor Sentiment
| AGIO Stock | USD 27.42 0.07 0.25% |
About 68% of Agios Pharm's investor base is looking to short. The analysis of the overall investor sentiment regarding Agios Pharm suggests that many traders are alarmed. Agios Pharm's investing sentiment overview a quick insight into current market opportunities from investing in Agios Pharm. Many technical investors use Agios Pharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 32
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Agios Pharm's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Agios Pharm.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Agios Historical Sentiment
Although Agios Pharm's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Agios, such as negative comments on social media and news outlets, may cause fear in the market and push Agios Pharm's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Agios.
Agios Pharm Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Agios Pharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Agios Pharm Historical Investor Sentiment
Investor biases related to Agios Pharm's public news can be used to forecast risks associated with an investment in Agios. The trend in average sentiment can be used to explain how an investor holding Agios can time the market purely based on public headlines and social activities around Agios Pharm. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Agios Pharm's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Agios Pharm and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Agios Pharm news discussions. The higher the estimate score, the more favorable the investor's outlook on Agios Pharm.
Agios Pharm Maximum Pain Price Across February 20th 2026 Option Contracts
Agios Pharm's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Agios Pharm close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Agios Pharm's options.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Agios Pharm's Stock prices. Below is the latest headlines and news related to Agios Pharm Stock. Current markets are strongly bullish. About 71% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Agios Pharm that are available to investors today. This information is accessible both publicly - through Agios Pharm's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Agios-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Agios Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Agios Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Agios Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Agios Pharm alpha.
Agios Largest EPS Surprises
Earnings surprises can significantly impact Agios Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2014-03-06 | 2013-12-31 | -0.34 | -0.4 | -0.06 | 17 | ||
2014-08-07 | 2014-06-30 | -0.4 | -0.54 | -0.14 | 35 | ||
2019-08-01 | 2019-06-30 | -1.7 | -1.87 | -0.17 | 10 | ||
2017-02-16 | 2016-12-31 | -1.51 | -1.34 | 0.17 | 11 | ||
2025-07-31 | 2025-06-30 | -1.75 | -1.93 | -0.18 | 10 | ||
2016-05-05 | 2016-03-31 | -0.79 | -0.61 | 0.18 | 22 |
There is far too much social signal, news, headlines, and media speculation about Agios Pharm that are available to investors today. This information is accessible both publicly - through Agios Pharm's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Agios-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Agios Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Agios Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Agios Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Agios Pharm alpha.
Agios Pharm Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Smith Cynthia of 2816 shares of Agios Pharm subject to Rule 16b-3 | 09/19/2025 |
2 | Disposition of 7472 shares by Cecilia Jones of Agios Pharm subject to Rule 16b-3 | 09/26/2025 |
3 | Disposition of 200 shares by Scadden David of Agios Pharm at 40.0 subject to Rule 16b-3 | 09/30/2025 |
4 | Agios Pharmaceuticals, Inc. Stock Analysis Exploring a 14 percent Upside Potential in the Biotech Sector - DirectorsTalk Interviews | 10/07/2025 |
5 | Agios Reports Third Quarter 2025 Financial Results and Provides Business Update | 10/30/2025 |
6 | Disposition of 2454 shares by Gheuens Sarah of Agios Pharm at 25.01 subject to Rule 16b-3 | 11/11/2025 |
7 | Why Shares in Agios Pharmaceuticals Got Crushed Today | 11/19/2025 |
8 | A Look at Agios Pharmaceuticalss Valuation After Mixed Results From RISE UP Mitapivat Trial | 11/20/2025 |
9 | Why Agios Pharmaceuticals May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data | 11/24/2025 |
10 | Agios Pharmaceuticals initiated with a Buy at Citi AGIO | 11/26/2025 |
11 | Why Agios Pharmaceuticals Is Down 7.1 percent After Phase 3 Sickle Cell Win With Mitapivat | 12/03/2025 |
Check out Agios Pharm Hype Analysis, Agios Pharm Correlation and Agios Pharm Performance. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.